Guia de apoio para avaliação de sintomalogia em doentes com síndromes mieloproliferativos através da  aplicação da escala mpn-10

Rocha, Andréia Maria Camargos; Valério, Elisabete; Ricou, Claudia; Sanchez, Juan; Freitas, Jorge; Caeiro, Márcia; Sarmento, Maria; Ponte, Sandra; Frias, Sónia

doi:10.31877/on.2018.36.01

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This questionnaire was translated into the Portuguese language and validated before this study (Sánchez et al, 2019). To standardize the application of the MPN-10 self-completion scale, the guidelines of the support guide for the symptoms' assessment in patients with myeloproliferative syndromes using the MPN-10 scale were considered (Rocha et al, 2018).…”

Section: Study Populationmentioning

confidence: 99%

Symptomatic burden amongst myeloproliferative neoplasm patients: mpn-10 prospective assessment in a portuguese cohort

Sarmento

Ponte

Monteiro

et al. 2021

journal

Self Cite

View full text Add to dashboard Cite

Introduction: Myeloproliferative neoplasms (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), significantly impact patients’ quality of life (QoL). The symptom burden assessment and continuous monitoring using the MPN Symptom Assessment Form Total Symptom Score (MPN-10) allows detecting symptomatic changes that may be signs of disease progression and can be used as an indicator of the need to reassess disease progression and/or therapeutic approach. Methods: Prospective multicenter registry of Portuguese MPN patients, including patients’ demographics and clinical characterization, and disease symptomatic burden based on MPN-10. Results: Overall, 324 patients were included, male to female ratio 0.7:1, median age 71 years old, median disease duration >3 years. Most patients had ET (63%), 24% PV, and 13% MF. Around 70% were being treated with hydroxyurea, 31% were on recommended low-dose aspirin, 9% needed phlebotomy, 4% received ruxolitinib, and <2% interferon. Most reported symptoms include fatigue, inactivity, itching, and concentration problems. PV and ET patients’ total symptom score significantly improved from baseline until last follow-up visit. The itching had a significant improvement over baseline for PV patients, as did fatigue, inactivity, concentration problems, and night sweats in ET patients. Conclusions: The systematic application of the MPN-10 led to a more in-depth knowledge of patients and their symptoms, which, together with analytical changes, motivated therapeutic readjustments that led to QoL gains. Future analysis of this cohort should be conducted to refine these results.

show abstract

Section: Study Populationmentioning

confidence: 99%